A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Summary

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.

Timeline

Start

2020-10-12

Primary completion

2021-12

Completion

2022-06

Drugs

Indications